Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REFRACT: Epcoritamab and Lenalidomide vs Standard Therapy in Relapsed/Refractory Follicular Lymphoma
NCT05848765Phase 2Recruiting
- Sponsor
- University of Birmingham
- Start
- Sep 2023
- Primary completion
- May 2029
- Modality
- Antibody Conjugates, Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of epcoritamab in follicular lymphoma (FL) (4 arms), sponsored by University of Birmingham. Primary endpoint: Complete metabolic response at 24 weeks. Started Sep 2023; status: recruiting.
02
Drugs
epcoritamab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT05848765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05848765.